You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

You are here

Annals of Internal Medicine and ACP Announce Recipients of Junior Investigator Recognition Award

CHICAGO, April 27, 2022 – Annals of Internal Medicine and the American College of Physicians (ACP) will honor Hanny Al-Samkari, MD and Muhammad R. A. Shipa, MBBS with Junior Investigator Recognition Awards at Internal Medicine Meeting 2022, ACP’s annual scientific meeting taking place April 28-30 in Chicago.

Annals’ Junior Investigator Recognition Awards are presented annually to early career physicians. Annals and ACP award the most outstanding article by a first author who is in an internal medicine residency program or a general medicine or internal medicine subspecialty fellowship program. An award is also given for the most outstanding article with a first author who is within three years of completing his or her training in internal medicine or one of its subspecialties.

Dr. Al-Samkari is an Assistant Professor of Medicine at Harvard Medical School and clinical investigator in the Massachusetts General Hospital (MGH) Division of Hematology Oncology. He serves as co-director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence, leading one of the largest HHT clinical trials programs in the United States. He is being recognized for an article he authored, “Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19,” that was published in the May 1, 2021, issue.

Dr. Shipa is currently pursuing his final year of PhD from University College London in B cell targeting therapy in SLE. He has received Versus Arthritis and LUPUS-UK grants to further extend his current research works. Dr. Shipa has also been working closely with the EULAR (European Alliance of associations for rheumatology) and EMEUNET (The emerging EULAR networking) as a working-member of the Visibility and Global affairs Subcommittee. He is being recognized for an article he authored, “Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus,” that was published in the December 21, 2021, issue.

Winners are selected based on the article’s novelty, methodological rigor, clarity of presentation, and potential to influence practice, policy or future research. Judges include Annals’ editors and representatives from Annals’ Editorial Board and the American College of Physicians’ Publication Committee.

# # #

About Annals of Internal Medicine

Annals of Internal Medicine is one of the most widely cited and influential medical journals in the world, with an impact factor of 25.391 – the highest of any specialty journal in its category. Annals’ mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research and contribute to improving the health of people worldwide. Established in 1927, Annals is the flagship journal of the American College of Physicians (ACP).

About the American College of Physicians

The American College of Physicians is the largest medical specialty organization in the United States with members in more than 145 countries worldwide. ACP membership includes 161,000 internal medicine physicians (internists), related subspecialists, and medical students. Internal medicine physicians are specialists who apply scientific knowledge and clinical expertise to the diagnosis, treatment, and compassionate care of adults across the spectrum from health to complex illness. Follow ACP on Twitter and Facebook, and Instagram.

Media Contact:
Addison Dunlap, American College of Physicians
215-351-2654
adunlap@acponline.org